BRI has a broad range of technologies available for licensing, including diagnostics, therapeutics, research materials and data analysis software. Explore our technology portfolio below.
Researchers at Benaroya Research Institute (BRI) have developed a method to express MHC II proteins in cell culture, form tetramers and bind them with synthetic peptides. The peptide sequences and the HLA types can be customized based on researcher’s needs. MHC II tetramers are fluorescently tagged, such that the T cells that recognize a unique MHC II:antigen complex will also be fluorescently tagged. This allows detection and isolation of the CD4+ T cells based on the T-cell receptor specificity using flow cytometry.
